The better choice depends on diagnosis, medical history, safety, side effects, insurance coverage, access, and long-term medical support
Americans now have access to the pill form of weight loss medication Wegovy, Danish drugmaker Novo Nordisk announced on Monday

Medications licensed for type 2 diabetes include: Exenatide (Byetta, Bydureon): Available as twice-daily injections or once-weekly extended-release formulation Liraglutide (Victoza): Administered as a once-daily subcutaneous injection at doses up to 1.8 mg for diabetes Dulaglutide (Trulicity): Once-weekly injection with pre-filled pen devices Semaglutide (Ozempic): Once-weekly injection for diabetes management Oral semaglutide (Rybelsus): The first oral GLP-1 agonist, taken daily For weight management specifically, two formulations have received UK marketing authorisation: Liraglutide 3.0 mg (Saxenda): Licensed for weight management in adults with a BMI 30 kg/m, or 27 kg/m with weight-related comorbidities Semaglutide 2.4 mg (Wegovy): Once-weekly injection approved for chronic weight management under similar BMI criteria It is crucial to understand that whilst these medications demonstrate efficacy in promoting weight loss, they are not specifically indicated for leptin resistance

Understanding what is typical can help you distinguish between expected, manageable symptoms and those that require prompt medical attention
How long do I need to stay on GLP-1